B.C based company could help revolutionize treatment of diabetes

  • 📰 TerraceStandard
  • ⏱ Reading Time:
  • 50 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 68%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Province invests almost $24 million into life-sciences firm Aspect Biosystems

A B.C.-based company could end up revolutionizing diabetes treatment and that is a reason why B.C. put up almost $24 million to keep it in B.C. rather than lose it to Denmark.

"So it's a very attractive company, if they are successful, and we think they will . It has the opportunity to completely revolutionize how people living with diabetes manage their diabetes and many other diseases as well." Looming behind B.C.'s move is the larger question of whether it is appropriate to use public funds to support a private company rather than let market forces play out.

Noting that B.C.'s economy is similar to that of Ireland, Bailey added that that country has used its tax system to build one of the largest life-sciences and pharmaceutical sectors in the world.Other examples abound. They include the European Union's Green New Deal and the Inflation Reduction Act in the United States — policies backed by hundreds of billions to achieve certain economic outcomes.

She also said that both the provincial and federal government go through a great deal of due diligence to protect the investment of taxpayers.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 24. in BR

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Vancouver company that 3-D prints live tissue for pancreas, liver implants receives $73-million from B.C., OttawaThe funding will help Aspect Biosystems build a manufacturing plant capable of producing materials for its clinical trials and investments to further develop its technology
Fonte: globebusiness - 🏆 31. / 66 Consulte Mais informação »